Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03646058 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

Study acronym: BUPRIS
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 2025 to Oct 2026 Completion date: Jan 2026 to Jan 2027 · Site contacts updated at 1 of 9 sitesv11 Show 2 more changesShow less
    • Completion date: Jan 2026 to Jan 2027
    • Site contacts updated at 1 of 9 sites
  2. Study sites: 10 to 9v10
  3. Study sites: 9 to 10v9
  4. Primary completion date: Oct 2023 to Oct 2025 Completion date: Jan 2024 to Jan 2026 · Eligibility criteria shortened, about 1 wordv8 Show 2 more changesShow less
    • Completion date: Jan 2024 to Jan 2026
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 10 to 9v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 11 to 10v6
  2. Primary completion date: Sep 2021 to Oct 2023 Completion date: May 2022 to Jan 2024 · Start date changed from estimate of Sep 2021 to Oct 10, 2021v5 Show 2 more changesShow less
    • Completion date: May 2022 to Jan 2024
    • Start date changed from estimate of Sep 2021 to Oct 10, 2021
  3. Trial status: Not Yet Recruiting to Recruiting Site details revised at 11 of 11 sitesv4 Show 1 more changeShow less
    • Site details revised at 11 of 11 sites
  4. Re-verified, no change to tracked fieldsv3
  5. Primary completion date: Sep 2020 to Sep 2021 Start date: Sep 2019 to Sep 2021 · Completion date: May 2021 to May 2022v2 Show 2 more changesShow less
    • Start date: Sep 2019 to Sep 2021
    • Completion date: May 2021 to May 2022
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims at investigating if adjunctive buprenorphine at low dose to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode, and at determining the most effective dose.
Trial Details
NCT Number NCT03646058
Lead Sponsor Centre Hospitalier Universitaire de Nīmes
Conditions Suicidal Ideation, Major Depressive Episode
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov